Why the study?
Does BMI category affect the blood pressure response to antihypertensive medications in male veterans?
Does BMI category affect the blood pressure response to antihypertensive medications in male veterans?
Obesity does not appear to cause resistance to antihypertensive medications, and obese patients may actually have better diastolic blood pressure control with atenolol compared to normal-weight patients.
Answers are grounded in this paper and cite their sources.
Atenolol may be considered for diastolic control in obese hypertensive men; challenges assumption of obesity-driven antihypertensive resistance.
Blood pressure increases with increasing body mass index (BMI) and BMI is linearly related to blood pressure in population studies. Obesity has been said to cause resistance to antihypertensive medications. We compared short-term and 1-year blood pressure response by BMI category and weight change with hydrochlorothiazide, atenolol, diltiazem-SR, captopril, clonidine, prazosin, or placebo in 1292 male veterans. Drug doses were titrated to achieve goal diastolic blood pressure <90 mm Hg over 4-8 weeks. Patients who achieved goal blood pressure were maintained for 1 year. BMI did not predict change in systolic, diastolic or pulse pressures during titration for any drug. At 1 year obese patients (BMI >30) were 2.5 times more likely to have diastolic blood pressure controlled by atenolol than normal weight (BMI <27) patients (p=0.01). Only prazosin patients gained weight: 1.7 lb (end-titration, p<0.0001; 1-year, p=0.02). Obesity does not appear to cause resistance to antihypertensive medications.
No takes yet. Share an insight, caveat, or question.
Materson et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: